The effects of alendronate and Vitamin K on postmenopausal osteoporosis

The effects of alendronate and Vitamin K Combination versus Alendronate alone on bone mineral density of patients with postmenopausal osteoporosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201504141479N3

Enrollment

Registered

2015-08-17

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis. postmenopausal osteoporosis

Interventions

Intervention 1: Group 1 will receive calcium + vitamin D pills twice daily (Jalinous company, Tehran, Iran, each pill contains 500 mg calcium carbonate and 200 IU vitamin D) and 70mg alendronate orall

Dr. Abidi Company, Tehran, Iran). The duration of treatment will be one year. Intervention 2: Group 2 will receive calcium + vitamin D pills twice daily (Jalinous company, Tehran, Iran, each pill cont

Dr. Abidi Company, Tehran, Iran) and vitamin K1 pills 10 mg daily (Pars Minoo Ind. Company, Tehran, Iran). The duration of treatment will be one year.

Treatment - Drugs

Group 1 will receive calcium + vitamin D pills twice daily (Jalinous company, Tehran, Iran, each pill contains 500 mg calcium carbonate and 200 IU vitamin D) and 70mg alendronate orally per week (Alen

Dr. Abidi Company, Tehran, Iran). The duration of treatment will be one year.

Group 2 will receive calcium + vitamin D pills twice daily (Jalinous company, Tehran, Iran, each pill contains 500 mg calcium carbonate and 200 IU vitamin D), 70mg alendronate orally per week (Alenate

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Osteoporosis according to WHO Criteria 2-Age:45-65 years 3- Postmenopausal women Exclusion criteria 1- Secondary Osteoporosis 2- Taking anticoagulants 3- History of liver and kidney disorders 4- History of Bisphosphonates side effects 5- People who have contraindications to take calcium and vitamin D 6- People who take other anti- osteoporotic medications 7- People who needs to use Vit.K in the alendronate group

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bone mineral density. Timepoint: Before the intervention and one year later. Method of measurement: By Densitometery with DXA method.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: Every 2 months. Method of measurement: Taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hassan Jokar

Imam Reza Hospital

jokarmh@mums.ac.ir+98 51 3859 8818

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026